ProQR

ProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands. ProQR was founded in 2012 by CEO Daniel de Boer and co-founders Henri Termeer,[1][2][3] Dinko Valerio[3][4] and Gerard Platenburg.[3][4] The company’s current pipeline includes potential treatments for rare genetic diseases[5] including Leber's congenital amaurosis, (LCA10)[5][6] dystrophic epidermolysis bullosa[5][6] and Usher syndrome.[7]

ProQR
Public
Traded asNASDAQ: PRQR
IndustryBiotechnology Pharmaceuticals
Founded2012
Headquarters
LEIDEN
Key people
Daniel de Boer (CEO)
ProductsDeveloping transformative RNA medicines
Number of employees
  • 150
Websitehttp://www.proqr.com/

ProQR is targeting genetic diseases by focusing on making changes to the RNA[8]. The firm's RNA editing technology, called Axiomer[7], can make targeted single nucleotide changes to RNA.

One of the company’s lead candidates[9], QR-110, is being developed to treat LCA10[10]. The substance acts by binding the mutated section of the RNA which will allow a formation of a normal CEP290 protein[11].

References
  1. Weisman, Robert (January 20, 2018). "Henri Termeer isn't exactly settling into retirement". The Boston Globe.
  2. McBride, Ryan (May 10, 2013). "Henri Termeer rediscovers the 'Genzyme feel' in world of biotech startups". FierceBiotech.
  3. Carroll, John (Sep 9, 2014). "Termeer-backed ProQR lays out terms for $75M IPO". FierceBiotech.
  4. Taylor, Nick Paul (Sep 13, 2017). "ProQR spins out CNS assets to form RNA rare disease biotech". FierceBiotech.
  5. Rodríguez Fernández, Clara (March 12, 2018). "A Dutch Company on the Quest Against Cystic Fibrosis". LaBiotech.eu.
  6. Rossi, Krista (May 25, 2018). "Daniel de Boer, CEO of ProQR, Explains RNA Treatment, QR-313, for DEB". Rare Disease Report.
  7. Dale, Alex (Feb 13, 2018). "ProQR Tackles Blindness Caused by a Rare". LaBiotech.eu.
  8. "The Art of Editing RNA". Research & Development. 2017-09-22. Retrieved 2018-10-04.
  9. Mathias, Tamara. "ProQR soars as childhood blindness drug succeeds in early trial". U.S. Retrieved 2018-10-04.
  10. Kilgore, Tomi. "ProQR's stock rockets to pace all gainers after upbeat drug trial results". MarketWatch. Retrieved 2018-10-04.
  11. "Proqr hits the gas on blindness project". Evaluate.com. Retrieved 2018-10-04.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.